Union Bancaire Privee UBP SA Invests $1.55 Million in Gilead Sciences, Inc. (NASDAQ:GILD)

Union Bancaire Privee UBP SA purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 16,732 shares of the biopharmaceutical company’s stock, valued at approximately $1,546,000.

Several other large investors also recently made changes to their positions in the stock. Delta Financial Group Inc. bought a new stake in shares of Gilead Sciences during the 4th quarter worth about $374,000. Atlantic Family Wealth LLC bought a new stake in Gilead Sciences during the 4th quarter valued at approximately $370,000. Pavion Blue Capital LLC bought a new stake in Gilead Sciences during the 4th quarter valued at approximately $217,000. Howard Capital Management Inc. boosted its stake in Gilead Sciences by 12.2% during the 4th quarter. Howard Capital Management Inc. now owns 41,922 shares of the biopharmaceutical company’s stock valued at $3,872,000 after purchasing an additional 4,574 shares during the period. Finally, Wealthspire Advisors LLC bought a new stake in Gilead Sciences during the 4th quarter valued at approximately $248,000. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares in the company, valued at $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 713,000 shares of company stock worth $67,945,181. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Down 0.1 %

NASDAQ GILD opened at $109.95 on Monday. The firm has a market cap of $137.03 billion, a PE ratio of 297.16, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $111.03. The stock’s 50 day simple moving average is $95.41 and its 200 day simple moving average is $88.83. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.87%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 832.43%.

Analyst Upgrades and Downgrades

GILD has been the subject of several recent analyst reports. UBS Group increased their target price on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Piper Sandler increased their target price on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Wolfe Research initiated coverage on Gilead Sciences in a research note on Friday, November 15th. They set an “outperform” rating and a $110.00 target price for the company. Mizuho increased their target price on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Finally, Wells Fargo & Company upped their price target on Gilead Sciences from $105.00 to $120.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $102.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.